Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Randomized, Double-blind, Placebo-controlled, Multi-center Study of STMC-103H in Neonates and Infants at Risk for Developing Allergic Disease

Next Previous
Trial Profile

A Phase 1b/2, Randomized, Double-blind, Placebo-controlled, Multi-center Study of STMC-103H in Neonates and Infants at Risk for Developing Allergic Disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STMC 103H (Primary)
  • Indications Allergic asthma; Atopic dermatitis; Food hypersensitivity; Immediate hypersensitivity
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADORED
  • Sponsors Siolta Therapeutics

Most Recent Events

  • 10 Dec 2025 According to a Siolta Therapeutics media release, one-year results from the phase 2 ADORED clinical trial of STMC-103H in infants at risk of developing atopic diseases have been accepted as a late-breaking oral presentation at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, to be held in Philadelphia from February 27 to March 2, 2026.
  • 20 Nov 2025 Status changed from active, no longer recruiting to completed.
  • 17 Nov 2025 According to a Siolta Therapeutics media release, the trial enrolled across 30 sites United States and Australia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top